| |
|
|
|
Summit Therapeutics plc  
|
|
1.57 0.01 (0.01%) |
11-21 11:46 |
|
Open: |
1.6 |
Pre close: |
1.56 |
Target:
|
1.99
|
|
High: |
1.582 |
Low: |
1.56 |
Resistance:
|
1.71
1.84
|
|
Volume: |
5,817 |
Market Cap: |
49M |
Support:
|
1.49
1.24
|
|
|
|
|
|
Technical Analysis |
|
Moving Averages |
MA(5):
|
1.56
 |
MACD |
MACD(12,26):
|
-0.03 |
|
MA(20): |
1.63  |
Signal(12,26,9): |
-0.01 |
|
MA(100): |
1.47 |
Stochastic Oscillator |
%K(14,3):
|
27.54 |
|
MA(250): |
1.54 |
%D(3): |
25.48 |
|
Average Volume(K) |
3-Month: |
3957
|
52-Week |
High:
|
2.46 |
|
10-Days: |
2113 |
Low: |
1.10 |
|
RSI |
RSI(14):
|
46.13 |
Change(%): |
17.2 |
|
Financials, Statistics and Valuation |
|
EPS |
1.225 |
Return on Equity (ttm) |
-67.3 |
Shares Out. (M) |
32.10 |
|
EPS Est. Current Year |
-0.530 |
Return on Assets (ttm) |
-33.4 |
Shares Float (M) |
12.05 |
|
EPS Est. Next Year |
-1.050 |
PEG Ratio |
0.00 |
% Held by Insiders |
48.71 |
|
EPS Est. Next Quarter |
-0.620 |
Qtrly Rev. Growth |
-89.4 |
% Held by Institutions |
9.00 |
|
Forward EPS |
-1.971 |
Gross Profit (p.s.) |
1.795 |
Shares Short (K) |
496 |
|
Book Value (p.s.) |
2.260 |
EBITDA (p.s.) |
0.000 |
P/E |
1.28 |
|
Sales Per Share |
0.000 |
Qtrly Earnings Growth |
0.00 |
P/BV |
0.69 |
|
Profit Margin |
-114.75 |
Operating Cash Flow
(M) |
0.00 |
P/S |
0.00 |
|
Operating Margin |
0.00 |
Levered Free Cash Flow
(M) |
0.00 |
P/CF |
0.00 |
|
|
|
|
|
|
